• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

    11/14/24 4:37:49 PM ET
    $SLGL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SLGL alert in real time by email
    SC 13G/A 1 armistice-slgl093024a1.htm



     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G/A

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*



    Sol-Gel Technologies Ltd.

    (Name of Issuer)

     

    Ordinary Shares, par value NIS 0.1 per share

    (Title of Class of Securities)

     

    M8694L103

    (CUSIP Number)

     

     

    September 30, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     


     

    CUSIP No.  M8694L103
     SCHEDULE 13G/A
    Page 2 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Armistice Capital, LLC
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    Delaware
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,463,104
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,463,104
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,463,104
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.99%
    12
    TYPE OF REPORTING PERSON
     
    IA, OO

     


     

    CUSIP No.  M8694L103
     SCHEDULE 13G/A
    Page 3 of 8 Pages

     

             
    1
    NAME OF REPORTING PERSONS
     
    Steven Boyd
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) o
    (b) o
     
    3
    SEC USE ONLY
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
    United States of America
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5
    SOLE VOTING POWER
     
    0
    6
    SHARED VOTING POWER
     
    1,463,104
    7
    SOLE DISPOSITIVE POWER
     
    0
    8
    SHARED DISPOSITIVE POWER
     
    1,463,104
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
    1,463,104
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
     
     
    o
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
    4.99%
    12
    TYPE OF REPORTING PERSON
     
    IN, HC

     


     

     

    CUSIP No. M8694L103
     SCHEDULE 13G/A
    Page 4 of 8 Pages

     

    Item 1.(a) Name of Issuer

    Sol-Gel Technologies Ltd.

    Item 1.(b) Address of Issuer’s Principal Executive Offices

    7 Golda Meir Street

    Ness Ziona 7493650, Israel

    Item 2.(a) Names of Person Filing:

    Armistice Capital, LLC

    Steven Boyd

    Collectively, the "Reporting Persons"

      

    Item 2.(b) Address of Principal Business Office:

     

    Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

     

    Steven Boyd

    c/o Armistice Capital, LLC

    510 Madison Avenue, 7th Floor

    New York, New York 10022

    United States of America

      

    Item 2.(c) Citizenship:

     

    Armistice Capital, LLC - Delaware

    Steven Boyd - United States of America

      

    Item 2.(d) Title of Class of Securities

     

    Ordinary Shares, par value NIS 0.1 per share (“Shares”)

     

    Item 2.(e) CUSIP No.:

    M8694L103

     

    CUSIP No.  M8694L103
     SCHEDULE 13G/A
    Page 5 of 8 Pages

     

     

    Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

      (a) ¨ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
     
      (b) ¨ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
     
      (c) ¨ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
     
      (d) ¨ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
      (e) x An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
      (f) ¨ An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
      (g) x A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
      (h) ¨ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
      (i) ¨ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
      (j) ¨ A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
      (k) ¨ A group, in accordance with §240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution:                            
           

     

    CUSIP No. M8694L103
     SCHEDULE 13G/A
    Page 6 of 8 Pages

     

     

    Item 4. Ownership

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

    (a) Amount beneficially owned as of September 30, 2024:

    Armistice Capital, LLC - 1,463,104

    Steven Boyd - 1,463,104   

    (b) Percent of Class as of September 30, 2024:

    Armistice Capital, LLC - 4.99%

    Steven Boyd - 4.99% 

    (c) Number of shares as to which the person has:

    (i) Sole power to vote or to direct the vote

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (ii) Shared power to vote or to direct the vote

    Armistice Capital, LLC - 1,463,104

    Steven Boyd - 1,463,104  

    (iii) Sole power to dispose or to direct the disposition of

    Armistice Capital, LLC - 0

    Steven Boyd - 0 

    (iv) Shared power to dispose or to direct the disposition of

    Armistice Capital, LLC - 1,463,104

    Steven Boyd - 1,463,104

     

    The percentage of Shares reported to be beneficially owned by the Reporting Persons are based on information from the Issuer.

    Armistice Capital, LLC (“Armistice Capital”) is the investment manager of Armistice Capital Master Fund Ltd. (the "Master Fund"), the direct holder of the Shares, and pursuant to an Investment Management Agreement, Armistice Capital exercises voting and investment power over the securities of the Issuer held by the Master Fund and thus may be deemed to beneficially own the securities of the Issuer held by the Master Fund. Mr. Boyd, as the managing member of Armistice Capital, may be deemed to beneficially own the securities of the Issuer held by the Master Fund. The Master Fund specifically disclaims beneficial ownership of the securities of the Issuer directly held by it by virtue of its inability to vote or dispose of such securities as a result of its Investment Management Agreement with Armistice Capital.

     

    Item 5. Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person

    The Master Fund, a Cayman Islands exempted company that is an investment advisory client of Armistice Capital, has the right to receive dividends from, or the proceeds from the sale of, the reported securities.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group

    Not Applicable.

    Item 9. Notice of Dissolution of Group 

    Not Applicable.

    Item 10. Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
    CUSIP No. M8694L103
     SCHEDULE 13G/A
    Page 7 of 8 Pages

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: November 14, 2024

     

     

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

           

     

     
    CUSIP No. M8694L103
     SCHEDULE 13G/A
    Page 8 of 8 Pages

     

    Exhibit I

     

    JOINT FILING STATEMENT

     

    PURSUANT TO RULE 13d-1(k)

     

    The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G/A, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G/A, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate.

     

    Dated: November 14, 2024

     

     

    Armistice Capital, LLC

           
      By:  /s/ Steven Boyd
       

    Steven Boyd

    Managing Member

           
     

     
      By:  /s/ Steven Boyd
       

    Steven Boyd

           
    Get the next $SLGL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SLGL

    DatePrice TargetRatingAnalyst
    8/19/2024$6.00 → $4.00Strong Buy → Outperform
    Raymond James
    10/21/2022$5.50Hold
    Jefferies
    11/15/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    11/12/2021$23.00 → $21.00Strong Buy
    Raymond James
    7/28/2021$20.00 → $21.00Buy
    HC Wainwright & Co.
    7/12/2021$21.00 → $20.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $SLGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Sol-Gel downgraded by Raymond James with a new price target

      Raymond James downgraded Sol-Gel from Strong Buy to Outperform and set a new price target of $4.00 from $6.00 previously

      8/19/24 6:57:49 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jefferies resumed coverage on Sol-Gel with a new price target

      Jefferies resumed coverage of Sol-Gel with a rating of Hold and set a new price target of $5.50

      10/21/22 7:42:15 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sol-Gel Technologies with a new price target

      HC Wainwright & Co. reiterated coverage of Sol-Gel Technologies with a rating of Buy and set a new price target of $20.00 from $21.00 previously

      11/15/21 1:18:47 PM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    SEC Filings

    See more
    • SEC Form EFFECT filed by Sol-Gel Technologies Ltd.

      EFFECT - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/9/25 12:15:15 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B3 filed by Sol-Gel Technologies Ltd.

      424B3 - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/8/25 10:24:35 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 6-K/A filed by Sol-Gel Technologies Ltd.

      6-K/A - Sol-Gel Technologies Ltd. (0001684693) (Filer)

      5/8/25 9:38:47 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TWYNEO issued to SOL-GEL TECHNOLOGIES LTD

      Submission status for SOL-GEL TECHNOLOGIES LTD's drug TWYNEO (ORIG-1) with active ingredient TRETINOIN;BENZOYL PEROXIDE has changed to 'Approval' on 07/26/2021. Application Category: NDA, Application Number: 214902, Application Classification: Type 4 - New Combination

      7/27/21 10:39:03 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sol-Gel Announces Reverse Share Split

      NESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the "Company") (NASDAQ:SLGL), a clinical-stage dermatology company, today announced a reverse share split (the "Reverse Split") of the Company's issued and outstanding ordinary shares, par value NIS 0.1 per share (the "Ordinary Shares"), at the ratio of 10-for-1, such that each ten (10) Ordinary Shares shall be consolidated into one (1) Ordinary Share. The Company obtained shareholders' approval for the Reverse Split at a ratio of between 2:1 and 10:1 at a special meeting of shareholders, which took place on April 1, 2025. The Company's board of directors then approved the Reverse Split ratio of 10-for-1 on Ap

      5/1/25 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.

      Sol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial top-line results are expected in the fourth quarter of 2026; a significant milestone in the clinical trial of recruiting more than 80% of the patients has been achievedSol-Gel now estimates the U.S. market potential for SGT-610 to be between $400 to $500 million annuallySGT-210 Phase 1b trial in Darier patients is ongoing; 50% of the patients have already completed the trial NESS ZIONA, Israel, April 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL

      4/17/25 8:40:29 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement

      NESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that it has received an extension of the period to regain compliance with The Nasdaq Stock Market LLC's ("Nasdaq") minimum bid price rule. On November 19, 2024, the Company received a letter from Nasdaq notifying the Company that, while the Company has not regained compliance with the Minimum Bid Price Requirement, Nasdaq has d

      11/20/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Financials

    Live finance-specific insights

    See more
    • Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments

      An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib gel, 2%), an Orphan Drug candidate with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome and partnered with Galderma to commercialize two approved lar

      3/13/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate Update

      Positive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Phase 1 trial for SGT-210 (erlotinib) demonstrated no systemic absorption-related adverse events; Sol-Gel intends to advance this drug candidate Sol-Gel has cash runway into the second half of 2025 NESS ZIONA, Israel, May 12, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products, EPSOLAY and TWYNEO, that were launched in the U.S., SGT-610, which is Phase 3

      5/12/23 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Reports Full-Year 2022 Financial Results and Corporate Developments

      Recent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase 3 study of SGT-610 is expected to initiate in the second half of 2023, with results expected by the end of 2025The base of recurrent TWYNEO® prescribers was 82% in Q4 2022, while the EPSOLAY® recurrent prescriber base has grown to 64% during the same periodFollowing recent financing, Sol-Gel's cash runway expected to extend into the second half of 2025 NESS ZIONA, Israel, March 10, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company wi

      3/10/23 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Leadership Updates

    Live Leadership Updates

    See more
    • Sol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

      Mori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept study in patients suffering from Darier disease is ongoing NESS ZIONA, Israel, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the third quarter ended September

      11/15/24 7:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Growth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel's cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA, Israel, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today financial results for the third quarter ended September 30, 2022 and provided a corporate update. Alon Seri-Levy, PhD, Chief Executive Officer of Sol-Gel, stated, "We are very pleased with the continu

      11/10/22 4:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sol-Gel Technologies Appoints Michael Glezin Vice President, Business Development

      NESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, announced today the appointment of Michael Glezin to the position of Vice President, Business Development. In this position, Mr. Glezin will be responsible for identifying new in-licensing business opportunities as well as potential commercial partners for the Company's approved products in ex-US territories. "We are very pleased to have Michael join the Company as we expand our business development efforts," stated Alon Seri-Levy,

      10/3/22 8:00:00 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SLGL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

      SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      11/14/24 4:37:49 PM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sol-Gel Technologies Ltd.

      SC 13G/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      11/14/24 6:17:23 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Sol-Gel Technologies Ltd. (Amendment)

      SC 13D/A - Sol-Gel Technologies Ltd. (0001684693) (Subject)

      4/8/24 9:28:09 AM ET
      $SLGL
      Biotechnology: Pharmaceutical Preparations
      Health Care